Economic analysis of finasteride

A model-based approach using data from the Proscarρ long-term efficacy and safety study

Peter C. Albertsen, James M. Pellissier, Franklin C. Lowe, Cynthia J. Girman, Claus G. Roehrborn

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in older men in the United States. BPH is often associated with a reduction in quality of life and may progress to acute urinary retention (AUR), the inability to pass any urine. Recently, a 4-year placebo-controlled clinical trial known as the Proscar® Long-Term Efficacy and Safety Study (PLESS) demonstrated that finasteride use reduces the risk of developing AUR by 57% and the need for BPH-related surgery by 55%. The economic implications of these findings were investigated using a model-based decision-analytic approach to compare finasteride with both watchful waiting and α-blocker therapy. The modeling used the longest-term published controlled data concerning α-blockers, which were for the α-blocker terazosin. The base case considered a 64-year-old man (the mean age of a PLESS patient) with prostatic enlargement on digital rectal examination and moderate-to-severe symptoms of BPH. The model suggested savings in surgical and AUR costs with finasteride versus watchful waiting, with an estimated 25% of total finasteride costs recouped in savings on surgical events avoided in the first year. Over 2 years, the expected cost per patient starting finasteride therapy was $2304, whereas the expected cost per patient starting terazosin was $2334. Analyses also explored the variation in economic results by baseline levels of prostate-specific antigen (PSA), a proxy for prostate volume. For patients with PSA levels ≥1.4 ng/mL, expected 2-year costs with finasteride and terazosin were $2342 and $2479, respectively. For patients with PSA levels ≥3.3 ng/mL, expected 2-year costs with finasteride were $373 less than with terazosin ($2347 vs $2720). Results were robust over a range of model assumptions and cost estimates. The analyses illustrate that all medical interventions, including watchful waiting, have associated costs. Finasteride shows cost offsets compared with watchful waiting and cost savings compared with terazosin over 2 years. Finasteride appears to be more economical in men with higher PSA levels.

Original languageEnglish (US)
Pages (from-to)1006-1024
Number of pages19
JournalClinical Therapeutics
Volume21
Issue number6
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Finasteride
Terazosin
Economics
Safety
Costs and Cost Analysis
Watchful Waiting
Prostatic Hyperplasia
Prostate-Specific Antigen
Urinary Retention
Digital Rectal Examination
Cost Savings
Controlled Clinical Trials
Proxy
Patient Safety
Prostate

Keywords

  • Benign prostatic hyperplasia
  • Cost-minimization analysis
  • Finasteride
  • Proscar® Long-Term Efficacy and Safety Study
  • α-blockers

ASJC Scopus subject areas

  • Pharmacology

Cite this

Economic analysis of finasteride : A model-based approach using data from the Proscarρ long-term efficacy and safety study. / Albertsen, Peter C.; Pellissier, James M.; Lowe, Franklin C.; Girman, Cynthia J.; Roehrborn, Claus G.

In: Clinical Therapeutics, Vol. 21, No. 6, 1999, p. 1006-1024.

Research output: Contribution to journalArticle

Albertsen, Peter C. ; Pellissier, James M. ; Lowe, Franklin C. ; Girman, Cynthia J. ; Roehrborn, Claus G. / Economic analysis of finasteride : A model-based approach using data from the Proscarρ long-term efficacy and safety study. In: Clinical Therapeutics. 1999 ; Vol. 21, No. 6. pp. 1006-1024.
@article{745efaf502aa4de6a47ff241c7e66f53,
title = "Economic analysis of finasteride: A model-based approach using data from the Proscarρ long-term efficacy and safety study",
abstract = "Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in older men in the United States. BPH is often associated with a reduction in quality of life and may progress to acute urinary retention (AUR), the inability to pass any urine. Recently, a 4-year placebo-controlled clinical trial known as the Proscar{\circledR} Long-Term Efficacy and Safety Study (PLESS) demonstrated that finasteride use reduces the risk of developing AUR by 57{\%} and the need for BPH-related surgery by 55{\%}. The economic implications of these findings were investigated using a model-based decision-analytic approach to compare finasteride with both watchful waiting and α-blocker therapy. The modeling used the longest-term published controlled data concerning α-blockers, which were for the α-blocker terazosin. The base case considered a 64-year-old man (the mean age of a PLESS patient) with prostatic enlargement on digital rectal examination and moderate-to-severe symptoms of BPH. The model suggested savings in surgical and AUR costs with finasteride versus watchful waiting, with an estimated 25{\%} of total finasteride costs recouped in savings on surgical events avoided in the first year. Over 2 years, the expected cost per patient starting finasteride therapy was $2304, whereas the expected cost per patient starting terazosin was $2334. Analyses also explored the variation in economic results by baseline levels of prostate-specific antigen (PSA), a proxy for prostate volume. For patients with PSA levels ≥1.4 ng/mL, expected 2-year costs with finasteride and terazosin were $2342 and $2479, respectively. For patients with PSA levels ≥3.3 ng/mL, expected 2-year costs with finasteride were $373 less than with terazosin ($2347 vs $2720). Results were robust over a range of model assumptions and cost estimates. The analyses illustrate that all medical interventions, including watchful waiting, have associated costs. Finasteride shows cost offsets compared with watchful waiting and cost savings compared with terazosin over 2 years. Finasteride appears to be more economical in men with higher PSA levels.",
keywords = "Benign prostatic hyperplasia, Cost-minimization analysis, Finasteride, Proscar{\circledR} Long-Term Efficacy and Safety Study, α-blockers",
author = "Albertsen, {Peter C.} and Pellissier, {James M.} and Lowe, {Franklin C.} and Girman, {Cynthia J.} and Roehrborn, {Claus G.}",
year = "1999",
doi = "10.1016/S0149-2918(99)80021-6",
language = "English (US)",
volume = "21",
pages = "1006--1024",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Economic analysis of finasteride

T2 - A model-based approach using data from the Proscarρ long-term efficacy and safety study

AU - Albertsen, Peter C.

AU - Pellissier, James M.

AU - Lowe, Franklin C.

AU - Girman, Cynthia J.

AU - Roehrborn, Claus G.

PY - 1999

Y1 - 1999

N2 - Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in older men in the United States. BPH is often associated with a reduction in quality of life and may progress to acute urinary retention (AUR), the inability to pass any urine. Recently, a 4-year placebo-controlled clinical trial known as the Proscar® Long-Term Efficacy and Safety Study (PLESS) demonstrated that finasteride use reduces the risk of developing AUR by 57% and the need for BPH-related surgery by 55%. The economic implications of these findings were investigated using a model-based decision-analytic approach to compare finasteride with both watchful waiting and α-blocker therapy. The modeling used the longest-term published controlled data concerning α-blockers, which were for the α-blocker terazosin. The base case considered a 64-year-old man (the mean age of a PLESS patient) with prostatic enlargement on digital rectal examination and moderate-to-severe symptoms of BPH. The model suggested savings in surgical and AUR costs with finasteride versus watchful waiting, with an estimated 25% of total finasteride costs recouped in savings on surgical events avoided in the first year. Over 2 years, the expected cost per patient starting finasteride therapy was $2304, whereas the expected cost per patient starting terazosin was $2334. Analyses also explored the variation in economic results by baseline levels of prostate-specific antigen (PSA), a proxy for prostate volume. For patients with PSA levels ≥1.4 ng/mL, expected 2-year costs with finasteride and terazosin were $2342 and $2479, respectively. For patients with PSA levels ≥3.3 ng/mL, expected 2-year costs with finasteride were $373 less than with terazosin ($2347 vs $2720). Results were robust over a range of model assumptions and cost estimates. The analyses illustrate that all medical interventions, including watchful waiting, have associated costs. Finasteride shows cost offsets compared with watchful waiting and cost savings compared with terazosin over 2 years. Finasteride appears to be more economical in men with higher PSA levels.

AB - Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in older men in the United States. BPH is often associated with a reduction in quality of life and may progress to acute urinary retention (AUR), the inability to pass any urine. Recently, a 4-year placebo-controlled clinical trial known as the Proscar® Long-Term Efficacy and Safety Study (PLESS) demonstrated that finasteride use reduces the risk of developing AUR by 57% and the need for BPH-related surgery by 55%. The economic implications of these findings were investigated using a model-based decision-analytic approach to compare finasteride with both watchful waiting and α-blocker therapy. The modeling used the longest-term published controlled data concerning α-blockers, which were for the α-blocker terazosin. The base case considered a 64-year-old man (the mean age of a PLESS patient) with prostatic enlargement on digital rectal examination and moderate-to-severe symptoms of BPH. The model suggested savings in surgical and AUR costs with finasteride versus watchful waiting, with an estimated 25% of total finasteride costs recouped in savings on surgical events avoided in the first year. Over 2 years, the expected cost per patient starting finasteride therapy was $2304, whereas the expected cost per patient starting terazosin was $2334. Analyses also explored the variation in economic results by baseline levels of prostate-specific antigen (PSA), a proxy for prostate volume. For patients with PSA levels ≥1.4 ng/mL, expected 2-year costs with finasteride and terazosin were $2342 and $2479, respectively. For patients with PSA levels ≥3.3 ng/mL, expected 2-year costs with finasteride were $373 less than with terazosin ($2347 vs $2720). Results were robust over a range of model assumptions and cost estimates. The analyses illustrate that all medical interventions, including watchful waiting, have associated costs. Finasteride shows cost offsets compared with watchful waiting and cost savings compared with terazosin over 2 years. Finasteride appears to be more economical in men with higher PSA levels.

KW - Benign prostatic hyperplasia

KW - Cost-minimization analysis

KW - Finasteride

KW - Proscar® Long-Term Efficacy and Safety Study

KW - α-blockers

UR - http://www.scopus.com/inward/record.url?scp=0032771836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032771836&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(99)80021-6

DO - 10.1016/S0149-2918(99)80021-6

M3 - Article

VL - 21

SP - 1006

EP - 1024

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -